Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | KCNA2 | P16389 | 2/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.32 |
| ▸ | KCNA1 | Q09470 | 2/20 | 0.32 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217807 | 0.90 | HDAC1 (0.34) | GRM2HDAC1HDAC6HDAC5ALOX5AP | |
| SCHEMBL23217850 | 0.82 | GRM2 (0.34) | GRM2HDAC1HDAC6HDAC5ALOX5AP | |
| SCHEMBL23217660 | 0.79 | KCNA3 (0.36) | KCNA2KCNA5KCNA1KCNA4KCNH2 | |
| SCHEMBL30010252 | 0.78 | TBXAS1 (0.41) | GRM2KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL23217685 | 0.78 | TBXAS1 (0.41) | GRM2KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL28772658 | 0.77 | HDAC1 (0.36) | GRM2HDAC1HDAC6HDAC5ALOX5AP | |
| SCHEMBL23217270 | 0.76 | KCNA2 (0.40) | KCNA2KCNA5KCNA1KCNA4KCNH2 | |
| SCHEMBL23217831 | 0.74 | CYP3A4 (0.43) | KCNA2KCNA5KCNA1KCNA4KCNH2 | |
| SCHEMBL23217812 | 0.72 | PTGDR2 (0.45) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL23218736 | 0.72 | GRM2 (0.39) | GRM2ALOX5APKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| CN-114555570-B | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555570-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | GRM2 4836/4885HDAC1 2211/4885HDAC6 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.